Skip to content
Elizabeth Holmes- Case Archive
personpersonLangly GeeLangly GeeFormer Theranos quality-control manager in the clinical laboratory.← All People
MentionedTheranos

Langly Gee

Former Theranos quality-control manager in the clinical laboratory.

MentionedFederal Criminal Trial
12 proceedings·12 mentions

About

Trial testimony identified Langly Gee as Theranos's clinical-laboratory quality-control or QA/QC manager. Erika Cheung said she reported quality-control information to him, sent him accumulated Edison data, and participated with him in proficiency-testing discussions.

Adam Rosendorff's examination and an email from Gee connected him to quality-system responsibilities and Edison quality-control reporting. Sunil Dhawan placed Gee among full-time personnel handling delegated daily laboratory functions and preparing technical materials for review. After consulting her notes, Lynette Sawyer corrected an earlier description and identified Gee as the QA/QC manager who received the sole delegation she recalled making.

Trial Record (12)

FederalFederal Criminal TrialAug 31, 2021 – Jan 3, 2022

Trial testimony identified Langly Gee as Theranos's clinical-laboratory quality-control or QA/QC manager, receiving Edison quality-control data and participating in proficiency-testing communications. Other testimony connected him to quality-system reporting and delegated laboratory functions.

Day 7

CrossErika Cheung — CrossErika CheungLance A. WadeMentioned

Summary

Defense counsel emphasized Theranos's trained laboratory teams, formal validation reports, multiple approvals, and written operating procedures while narrowing Cheung's personal expertise. Cheung agreed that QC preceded patient testing but maintained that validation was sometimes compressed, written procedures differed from practice, and frequent reader failures required extensive recalibration.

Mentioned in this proceeding.

Day 8

CrossErika Cheung — CrossErika CheungLance A. WadeMentioned

Summary

Defense counsel used laboratory procedures, email chains, workflow improvements, and a sample-volume patent to emphasize Theranos's monitoring and remediation systems and to narrow Cheung's expertise. Cheung nevertheless maintained that the vitamin D SOP was not followed, confirmed that hepatitis C was not run on Edison after her concerns, and described Edison as a one-patient, one-test device.

Mentioned in this proceeding.

Day 12

CrossAdam Rosendorff — CrossAdam RosendorffLance A. WadeMentioned

Summary

Defense counsel challenged Adam Rosendorff with his government-interview history, prior testimony, and laboratory records while examining his CLIA responsibility, management constraints, the restricted September 2013 launch, assay validation, and Theranos's quality and reporting systems.

Mentioned in this proceeding.

Day 13

CrossAdam Rosendorff — CrossAdam RosendorffLance A. WadeMentioned

Summary

Defense counsel challenged Adam Rosendorff with inspection records, compliance emails, signed Edison validation reports, quality-system data, and proficiency-testing records. Rosendorff acknowledged inspection cooperation, assay approvals, and predicate-device proficiency testing while maintaining that later Edison performance, incident management, and alternative testing remained deficient.

Mentioned in this proceeding.

Day 15

Day 16

RecrossAdam Rosendorff — RecrossAdam RosendorffLance A. WadeMentioned

Summary

Defense counsel used emails and prior testimony to challenge Adam Rosendorff on laboratory authority, HCG implementation, launch scope, and complaint frequency. Rosendorff made several concessions but preserved qualifications about operational control, quality-control failures, and limited recollection.

Mentioned in this proceeding.

Day 19

Day 20

Day 30

CrossLynette Sawyer — CrossLynette SawyerLance A. Wade1highlightMentioned

Summary

Lynette Sawyer agreed that her Theranos co-director role was limited and off-site, while emphasizing gaps in her knowledge of the company's LIS, nanotainers, and proprietary testing. Admitted emails documented her decision not to renew, her extension through June, and her formal departure.

Mentioned in this proceeding.

Highlights (1)

testimony highlightSawyer clarified after reviewing her notes that the one delegation she recalled went to QA/QC manager Langly Gee, not a technical supervisor, and concerned quality-control review and analysis.Open in transcript →